google-site-verification: googlec7193c3de77668c9.html

Framework can improve Alzheimer's treatment efficacy by tracking anti-Aβ therapy response

[
In the last few years, progress has been made in the fight against Alzheimer’s disease with a class of therapies called anti-amyloid antibodies (anti-Aβ). These monoclonal anti-Aβs are proteins made in a laboratory to stimulate the immune system to slow the progression of the disease by targeting amyloid plaques in the brain that are characteristic of Alzheimer’s.


Source link

Advertisements
Views: 2

See also  Kidderminster premises plea as wellbeing charity told to move

Check Also

Study identifies low sensitivity of standard, modified two-tiered testing for Lyme disease

[ For patients with early infection with Lyme disease (LD), standard and modified two-tiered testing …

A fresh take on the 'COVID Generation': How the pandemic may have changed young people for the better

[ At the peak of the pandemic in 2021, teenagers from Sackets Harbor, N.Y. got …

Working outside the home protected mental health for older adults during the pandemic, finds study

[ Credit: Unsplash/CC0 Public Domain New research using data from the Canadian Longitudinal Study on …

Leave a Reply

Available for Amazon Prime